A new antibody treatment for Alzheimer’s has apparently halted its progression in a small human trial.

The treatment lowers the amount of beta peptide in the brain, thought to be the cause of amyloid deposits that damage brain tissue and cause Alzheimer’s.



Richard Dodel and colleagues from the Friedrich-Wilhelms University in Bonn, Germany have given five patients with early Alzheimer’s the treatment, which involves intravenous injections of immunoglobulins containing antibodies against the peptide.



The researchers found that it reduced levels of the substance in the brain and prevented the worsening of Alzheimer’s symptoms.



More here.